Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?

IN BRIEF

Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to expire
in the next few years. Biosimilar insulins have the potential to reduce diabetes treatment costs, increase the accessibility
of insulin treatment, and expand the number of insulin brands available for those with diabetes. However, they will have to
overcome numerous regulatory hurdles, meet a variety of commercial demands, and effectively confront competition from both
established and next-generation branded insulin products before they can succeed on the global market.